

For CK, Sp-ADP $\alpha$ B isomer was a competitive inhibitor of the ADP phosphorylation. For PK, the Rp- and Sp-ADP $\alpha$ B isomers were poor competitive and non-competitive inhibitors, respectively. Preliminary results suggest that the Rp isomer of ADP $\alpha$ B is phosphorylated with comparable efficiency to natural NDPK substrates (GDP, CDP), whereas the Sp isomer is not recognized as a substrate. These enzymes are also being investigated for purification of the two isomers of ddNTP $\alpha$ B. An enzymatic separation where only the Rp isomer is phosphorylated would result in Rp-ddNTP $\alpha$ B and Sp-ddNDP $\alpha$ B, which can readily be separated by HPLC, and provide a straight forward means to investigate the purified isomers in antiviral studies.

doi:10.1016/j.antiviral.2008.01.148

135

Withdrawn.

doi:10.1016/j.antiviral.2008.01.149

136


### Ring-expanded Nucleosides (RENs) Exhibit Potent ATP-dependent Helicase Activity of RNA Helicase DDX3 with Little or no Toxicity in *Ex Vivo* Cell Culture or *In Vivo* in Mice

Venkat Yedavalli<sup>2,\*</sup>, Ning Zhang<sup>1</sup>, Hongyi Cai<sup>1</sup>, Kuan-Teh Jeang<sup>2</sup>, Ramachandra Hosmane<sup>1</sup>

<sup>1</sup> Laboratory for Drug Design & Synthesis, Department of Chemistry & Biochemistry, University of Maryland (UMBC), Baltimore, USA; <sup>2</sup> Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, USA

A series of ring expanded ("Fat") nucleoside (REN) analogues shown below were screened for inhibition of HIV-1

replication. We demonstrate that two compounds **NZ-46** and **NZ-51** inhibit the ATP dependent helicase activity of RNA helicase DDX3. These two compounds also suppressed HIV-1 replication in T cells and monocyte-derived macrophages. These compounds do not exhibit toxicity in *ex vivo* cell culture or *in vivo* in mice. We suggest that cellular RNA helicases can be attractive anti-viral targets for HIV-1 replication, which can circumvent the current problem of drug resistance associated with many anti-HIV drugs.



doi:10.1016/j.antiviral.2008.01.150